Bulleyaconitine A Inhibits Morphine-Induced Withdrawal Symptoms, Conditioned Place Preference, and Locomotor Sensitization Via Microglial Dynorphin A Expression

Bulleyaconitine A (BAA), a C19-diterpenoid alkaloid, has been prescribed as a nonnarcotic analgesic to treat chronic pain over four decades in China. The present study investigated its inhibition in morphine-induced withdrawal symptoms, conditioned place preference (CPP) and locomotor sensitization,...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Meng-Jing, Wang, Mi-Ya, Ma, Le, Ahmad, Khalil Ali, Wang, Yong-Xiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7953057/
https://www.ncbi.nlm.nih.gov/pubmed/33716748
http://dx.doi.org/10.3389/fphar.2021.620926

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7953057/
https://www.ncbi.nlm.nih.gov/pubmed/33716748
http://dx.doi.org/10.3389/fphar.2021.620926

Ejemplares similares